Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bitdeer Technologies Group (BTDR) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Bitdeer Technologies GroupTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Bitdeer Technologies Group — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B), while Bitdeer Technologies Group trades at $9.1 (market cap $2.36B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.1× Bitdeer Technologies Group's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.

	ACAD	BTDR
Market Cap	$5.07B	$2.36B
Sector	Health	Technology
52-Week High	$29.41	$25.90
52-Week Low	$20.06	$7.28
Enterprise Value	$4.19B	$3.85B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Bitdeer Technologies Group

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACAD

Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.PRNewsWire · 1 day agoBullish ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.Andrew Wynn · 2 days agoBullish View details →

BTDR

Bitdeer Technologies faces uncertainty despite strong revenue growth due to Bitcoin and AI market risks.Seeking Alpha · 1 day agoNeutral Stocks of INNOVATE Corp. and Bitdeer Technologies plunge over 20% despite positive earnings reports.Danny Green · 1 day agoBearish Bitdeer expands into AI infrastructure with a 16-year renewable energy data center lease in Norway.Tony Dante · 2 days agoNeutral View details →

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.